SpringerLink
Log in

Pharmacogenomics and Pediatrics

  • Reference work entry
  • First Online:
The ADME Encyclopedia

  • 77 Accesses

Synonyms

Pharmacogenetics: Genetic Science; Genetics

Pediatrics: Neonatology; Medical Specialty; Paediatrics; Medicine; Pedology; Pediatric medicine

Definition

Pharmacogenomics (PGx) offers the promise of precision medicine. Despite apparent enthusiasm for PGx, it remains unclear how much testing is used in clinical practice, especially within pediatric medicine. Pharmacogenomic testing can reveal individual genetic factors that contribute to either a lack of response to drug therapy or increased susceptibility to drug-related adverse events. Adverse drug reactions may be avoided or reduced when drug therapy is based on genetic information obtained from PGx testing. Dose selection to enhance therapeutic response and minimize lack of efficacy can also be guided by genetic information. For these reasons, PGx screening of patients before or during the use of certain medications is recommended by the US Food and Drug Administration (FDA) for applicable drugs [1]. However, less than full...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 802.49
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
EUR 962.99
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. USFDA, Silver Spring. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed Jun 2020.

  2. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care. 2004;10(7 Pt 1):425–32.

    PubMed  Google Scholar 

  3. Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, et al. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics. 2012;13(12):1405–17. https://doi.org/10.2217/pgs.12.124.

    Article  CAS  PubMed  Google Scholar 

  4. Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics. 2010;11(5):643–6. https://doi.org/10.2217/pgs.10.45.

    Article  PubMed  Google Scholar 

  5. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004;5(8):1139–49. https://doi.org/10.1517/14622416.5.8.1139.

    Article  PubMed  Google Scholar 

  6. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429–36. https://doi.org/10.1001/jama.2009.1420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Stintzing S, Heinemann V, Moosmann N, Hiddemann W, Jung A, Kirchner T. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. Dtsch Arztebl Int. 2009;106(12):202–6. https://doi.org/10.3238/arztebl.2009.0202.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Moen EL, Godley LA, Zhang W, Dolan ME. Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med. 2012;4(11):90. https://doi.org/10.1186/gm391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ni X, Zhang W, Huang RS. Pharmacogenomics discovery and implementation in genome-wide association studies era. Wiley Interdiscip Rev Syst Biol Med. 2013;5(1):1–9. https://doi.org/10.1002/wsbm.1199.

    Article  CAS  PubMed  Google Scholar 

  10. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med. 2011;13(12):987–95.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hahn U, Cohen KB, Garten Y, Shah NH. Mining the pharmacogenomics literature – a survey of the state of the art. Brief Bioinform. 2012;13(4):460–94. https://doi.org/10.1093/bib/bbs018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Campbell SC, Spigarelli MG. Pharmacology and pharmacogenomics of neurological medications used in pregnancy. Clin Obstet Gynecol. 2013;56(2):305–16. https://doi.org/10.1097/GRF.0b013e31828f241d.

    Article  PubMed  Google Scholar 

  13. Lee KC, Ma JD, Kuo GM. Pharmacogenomics: bridging the gap between science and practice. J Am Pharm Assoc (2003). 2010;50(1):e1–14; quiz e5–7. https://doi.org/10.1331/JAPhA.2010.09124.

    Article  Google Scholar 

  14. Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories E15. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 2007. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E15/Step4/E15_Guideline.pdf

  15. Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev. 2009;30(2):55–65.

    PubMed  PubMed Central  Google Scholar 

  16. Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J Pharm Pract. 2012;25(4):417–27. https://doi.org/10.1177/0897190012448309.

    Article  PubMed  Google Scholar 

  17. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther. 2009;16(6):554–61. https://doi.org/10.1097/MJT.0b013e318199fa17.

    Article  PubMed  Google Scholar 

  18. Brockmoller J, Tzvetkov MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol. 2008;64(2):133–57. https://doi.org/10.1007/s00228-007-0424-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mini E, Nobili S. Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab. 2009;6(1):17–24.

    PubMed  PubMed Central  Google Scholar 

  20. Court MH. A pharmacogenomics primer. J Clin Pharmacol. 2007;47(9):1087–103. https://doi.org/10.1177/0091270007303768.

    Article  CAS  PubMed  Google Scholar 

  21. Newman WG, Payne K, Tricker K, Roberts SA, Fargher E, Pushpakom S, et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genoty** prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011;12(6):815–26. https://doi.org/10.2217/pgs.11.32.

    Article  CAS  PubMed  Google Scholar 

  22. Hawcutt DB, Thompson B, Smyth RL, Pirmohamed M. Paediatric pharmacogenomics: an overview. Arch Dis Child. 2013;98(3):232–7. https://doi.org/10.1136/archdischild-2012-302852.

    Article  PubMed  Google Scholar 

  23. Stevens A, De Leonibus C, Hanson D, Whatmore A, Murray P, Donn R, et al. Pediatric perspective on pharmacogenomics. Pharmacogenomics. 2013;14(15):1889–905. https://doi.org/10.2217/pgs.13.193.

    Article  CAS  PubMed  Google Scholar 

  24. Leeder JS, Kearns GL. The challenges of delivering pharmacogenomics into clinical pediatrics. Pharmacogenomics J. 2002;2(3):141–3. https://doi.org/10.1038/sj.tpj.6500104.

    Article  CAS  PubMed  Google Scholar 

  25. Van Driest SL, McGregor TL. Pharmacogenetics in clinical pediatrics: challenges and strategies. Per Med. 2013;10(7). https://doi.org/10.2217/pme.13.70.

  26. Rieder M. New ways to detect adverse drug reactions in pediatrics. Pediatr Clin N Am. 2012;59(5):1071–92. https://doi.org/10.1016/j.pcl.2012.07.010.

    Article  Google Scholar 

  27. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450–8. https://doi.org/10.1038/clpt.2011.306.

    Article  CAS  PubMed  Google Scholar 

  28. McCullough KB, Formea CM, Berg KD, Burzynski JA, Cunningham JL, Ou NN, et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ. 2011;75(3):51. https://doi.org/10.5688/ajpe75351.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gokula M, Holmes HM. Tools to reduce polypharmacy. Clin Geriatr Med. 2012;28(2):323–41. https://doi.org/10.1016/j.cger.2012.01.011.

    Article  PubMed  Google Scholar 

  30. Parry CM, Hawcutt D. Fifteen-minute consultation: pharmacogenomics: a guide for busy clinicians. Arch Dis Child Educ Pract Ed. 2020;105(2):107–10. https://doi.org/10.1136/archdischild-2019-316971.

    Article  PubMed  Google Scholar 

  31. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–7. https://doi.org/10.1038/clpt.2012.96

  32. Kuo GM, Ma JD, Lee KC, Halpert JR, Bourne PE, Ganiats TG et al. Institutional Profile: University of California San Diego Pharmacogenomics Education Program (PharmGenEd): bridging the gap between science and practice. Pharmacogenomics. 2011;12(2):149–53. https://doi.org/10.2217/pgs.10.213

  33. Gregornik D, Salyakina D, Brown M, Roiko S, Ramos K. Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium. Pharmacogenomics J. 2020; https://doi.org/10.1038/s41397-020-00181-w.

  34. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics. 2010;11(3):439–48. https://doi.org/10.2217/pgs.10.8.

    Article  CAS  PubMed  Google Scholar 

  35. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012;125(16):1997–2005. https://doi.org/10.1161/CIRCULATIONAHA.111.070920.

    Article  CAS  PubMed  Google Scholar 

  36. Mahajan P, Meyer KS, Wall GC, Price HJ. Clinical applications of pharmacogenomics guided warfarin dosing. Int J Clin Pharm. 2011;33(1):10–9. https://doi.org/10.1007/s11096-011-9486-1.

    Article  CAS  PubMed  Google Scholar 

  37. Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am J Geriatr Pharmacother. 2009;7(4):197–203. https://doi.org/10.1016/j.amjopharm.2009.07.002.

    Article  PubMed  Google Scholar 

  38. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025–33. https://doi.org/10.1097/QAD.0b013e3283103ce6.

    Article  PubMed  Google Scholar 

  39. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genoty** in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14(6):335–42. https://doi.org/10.1097/00008571-200406000-00002.

    Article  PubMed  Google Scholar 

  40. Ware N, MacPhee IA. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr Opin Mol Ther. 2010;12(3):270–83.

    CAS  PubMed  Google Scholar 

  41. Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics. 2008;9(5):585–96. https://doi.org/10.2217/14622416.9.5.585.

    Article  CAS  PubMed  Google Scholar 

  42. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4(6):914–9. https://doi.org/10.1111/j.1600-6143.2004.00435.x.

    Article  CAS  PubMed  Google Scholar 

  43. Dionne F, Mitton C, Rassekh R, Brooks B, Ross C, Hayden M, et al. Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics J. 2012;12(3):205–13. https://doi.org/10.1038/tpj.2011.15.

    Article  CAS  PubMed  Google Scholar 

  44. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78. https://doi.org/10.1001/jama.2008.892.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Selkirk CG, Weissman SM, Anderson A, Hulick PJ. Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013;17(3):219–25. https://doi.org/10.1089/gtmb.2012.0165.

    Article  PubMed  Google Scholar 

  46. CYP2D6 pharmacogenomics of tamoxifen treatment. Technol Eval Cent Assess Program Exec Summ. 2008;23(1):1–4.

    Google Scholar 

  47. Flockhart D. CYP2D6 genoty** and the pharmacogenetics of tamoxifen. Clin Adv Hematol Oncol. 2008;6(7):493–4.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Wright State University Boonshoft School of Medicine/Dayton Children’s Hospital, Dayton, OH, USA

    Catherine M. Sherwin

Authors
  1. Catherine M. Sherwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine M. Sherwin .

Editor information

Editors and Affiliations

  1. University of La Plata (UNLP), Argentinian National Council of Scientific and Technical Research (CONICET), La Plata, Argentina

    Alan Talevi

Section Editor information

  1. Medicinal Chemistry, Department of Biological Sciences, Faculty of Exact Sciences, National University of la Plata (UNLP) - Argentinean National Council of Scientific and Technical Research (CONICET), La Plata, Buenos Aires, Argentina

    Alan Talevi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Sherwin, C.M. (2022). Pharmacogenomics and Pediatrics. In: Talevi, A. (eds) The ADME Encyclopedia. Springer, Cham. https://doi.org/10.1007/978-3-030-84860-6_21

Download citation

Publish with us

Policies and ethics

Search

Navigation